Inhibrx Gelecekteki Büyüme

Inhibrx is forecast to grow earnings and revenue by 9.1% and 59.7% per annum respectively while EPS is expected to grow by 13.1% per annum.

9.1%

Kazanç büyüme oranı

13.1%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.1%
Gelir büyüme oranı	59.7%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	13 May 2024

Güncelleme yok

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:INBX.V - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	122	-296	N/A	N/A	1
12/31/2025	2	-361	N/A	N/A	1
12/31/2024	N/A	-316	N/A	N/A	2
3/31/2024	2	-271	-222	-216	N/A
12/31/2023	2	-241	-198	-193	N/A
9/30/2023	0	-189	-169	-167	N/A
6/30/2023	1	-172	-144	-144	N/A
3/31/2023	1	-163	-129	-128	N/A
12/31/2022	2	-145	-116	-115	N/A
9/30/2022	5	-125	-108	-107	N/A
6/30/2022	7	-111	-91	-90	N/A
3/31/2022	7	-94	-87	-86	N/A
12/31/2021	7	-82	-81	-80	N/A
9/30/2021	7	-78	-74	-73	N/A
6/30/2021	11	-78	-75	-73	N/A
3/31/2021	13	-75	-64	-62	N/A
12/31/2020	13	-76	-49	-48	N/A
9/30/2020	10	-75	-46	-45	N/A
6/30/2020	6	-74	-33	-31	N/A
3/31/2020	6	-68	-36	-34	N/A
12/31/2019	13	-51	-34	-32	N/A
9/30/2019	15	-40	-29	-27	N/A
6/30/2019	15	-30	-29	-27	N/A
3/31/2019	14	-26	-28	-27	N/A
12/31/2018	9	-31	-25	-23	N/A
9/30/2018	7	-35	-24	-23	N/A
12/31/2017	8	-19	N/A	-19	N/A
12/31/2016	7	-8	N/A	-18	N/A

Kazançlar ve Tasarruf Oranları: INBX.V is forecast to remain unprofitable over the next 3 years.

Kazançlar ve Piyasa: INBX.V is forecast to remain unprofitable over the next 3 years.

Yüksek Büyüme Kazançları: INBX.V is forecast to remain unprofitable over the next 3 years.

Gelir ve Pazar: INBX.V's revenue (59.7% per year) is forecast to grow faster than the US market (8.5% per year).

Yüksek Büyüme Geliri: INBX.V's revenue (59.7% per year) is forecast to grow faster than 20% per year.

Gelecekteki ROE: Insufficient data to determine if INBX.V's Return on Equity is forecast to be high in 3 years time